Application of autologous SOX9+ airway basal cells in patients with bronchiectasis.

Bronchiectasis is a common condition and a leading cause of respiratory morbidity and mortality. The treatment method for bronchiectasis is mainly symptomatic treatment or surgery; however, this condition is extremely prone to recurrence. To preliminarily evaluate the safety and efficacy of applying SOX9+ autologous airway basal cells (BCs) in patients with bronchiectasis. SOX9+ BCs were isolated from microscale tissue of a grade 3-5 bronchus by bronchoscopic brushing and expanded in vitro for approximately 4 weeks. Subsequently, the autologous SOX9+ BCs were transplanted into the diseased bronchus to treat patients with bronchiectasis. The forced expiratory volume in1 second (FEV1)%, forced vital capacity (FVC)%, total lung capacity (TLC)%, residual volume (RV)% and RV/TLC ratio of predicted value in patients with bronchiectasis were improved at 4, 12, 24 and 48 weeks after cell transplantation, although the differences were not statistically significant (P > .05). Chest CT scans showed that the lesions in the pulmonary segment had not progressed at 4, 12 and 24 weeks after transplantation. No patients died during the follow-up. At 4, 12 and 24 weeks after transplantation, routine blood tests, liver function tests, renal function tests and myocardial enzymatic indexes were normal (P > .05). Transplantation of autologous SOX9+ BCs has positive effects and is safe for patients with bronchiectasis. © 2020 John Wiley & Sons Ltd.

Citation

Fengjun Sun, Lin Cheng, Haiqing Guo, Yufen Sun, Yu Ma, Yu Wang, Wei Feng, Qian Yuan, Xiaotian Dai. Application of autologous SOX9+ airway basal cells in patients with bronchiectasis. The clinical respiratory journal. 2020 Sep;14(9):839-848

Mesh Tags

Substances

PMID: 32436281

search → result